Morrow Sodali will act as Information Agent in the Pfizer - Medivation M&A deal.
The Companies have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
Related News
How Strategic Shareholder Engagement Helped Navigate a Critical Vote at Plug Power
18 February 2026
CII’s board of directors appoints the members and leaders of the 2026 Markets Advisory Council
13 February 2026
Sodali & Co Hires BlackRock Investment Stewardship AI and Data Lead
11 February 2026
Valor Econômico features Sodali & Co: Competitiveness hinges on data and governance
11 February 2026
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right